A novel treatment for refractory stoma prolapse using endoscopic‐assisted percutaneous sigmoidopexy

2021 ◽  
Author(s):  
Teppei Kamada ◽  
Hironori Ohdaira ◽  
Yutaka Suzuki
Keyword(s):  
Novel Treatment ◽  
Stoma Prolapse

Botulinum toxin as a novel treatment for self-mutilation in Lesch–Nyhan syndrome

2005 ◽  
Vol 47 (09) ◽  
pp. 636 ◽  
Author(s):  
Edward Dabrowski ◽  
Sarah A Smathers ◽  
Curt S Ralstrom ◽  
Michael A Nigro ◽  
Jimmie P Leleszi
Keyword(s):  
Botulinum Toxin ◽  
Novel Treatment ◽  
Self Mutilation

Novel treatment for walled-off necrosis (WON)

2009 ◽  
Vol 47 (05) ◽  
Author(s):  
Á Pap ◽  
M Burai ◽  
Á Tarpay
Keyword(s):  
Novel Treatment ◽  
Walled Off Necrosis

Új lehetőségek a refrakter és relabált Hodgkin-lymphomás betegek kezelésében

2015 ◽  
Vol 156 (45) ◽  
pp. 1824-1833 ◽  
Author(s):  
Árpád Illés ◽  
Ádám Jóna ◽  
Zsófia Simon ◽  
Miklós Udvardy ◽  
Zsófia Miltényi
Keyword(s):  
Stem Cell ◽  
Hodgkin Lymphoma ◽  
Treatment Options ◽  
Survival Rates ◽  
Relapse Free Survival ◽  
Term Survival ◽  
Free Survival ◽  
Novel Treatment ◽  
Refractory Hodgkin Lymphoma

Introduction: Hodgkin lymphoma is a curable lymphoma with an 80–90% long-term survival, however, 30% of the patients develop relapse. Only half of relapsed patients can be cured with autologous stem cell transplantation. Aim: The aim of the authors was to analyze survival rates and incidence of relapses among Hodgkin lymphoma patients who were treated between January 1, 1980 and December 31, 2014. Novel therapeutic options are also summarized. Method: Retrospective analysis of data was performed. Results: A total of 715 patients were treated (382 men and 333 women; median age at the time of diagnosis was 38 years). During the studied period the frequency of relapsed patients was reduced from 24.87% to 8.04%. The numbers of autologous stem cell transplantations was increased among refracter/relapsed patients, and 75% of the patients underwent transplantation since 2000. The 5-year overall survival improved significantly (between 1980 and 1989 64.4%, between 1990 and 1999 82.4%, between 2000 and 2009 88.4%, and between 2010 and 2014 87.1%). Relapse-free survival did not change significantly. Conclusions: During the study period treatment outcomes improved. For relapsed/refractory Hodgkin lymphoma patients novel treatment options may offer better chance for cure. Orv. Hetil., 2015, 156(45), 1824–1833.

Novel treatment opportunities in Graves’ orbitopathy

2014 ◽  
Vol 155 (33) ◽  
pp. 1295-1300
Author(s):  
Annamária Erdei ◽  
Annamária Gazdag ◽  
Miklós Bodor ◽  
Eszter Berta ◽  
Mónika Katkó ◽  
...  
Keyword(s):  
Clinical Experience ◽  
Clinical Course ◽  
Treatment Protocol ◽  
Treatment Modalities ◽  
Graves Disease ◽  
Novel Treatment ◽  
Graves Orbitopathy ◽  
Cd20 Antibody ◽  
Anti Cd20 ◽  
Novel Therapeutic

Graves’ orbitopathy is the most common extrathyroidal manifestation of Graves’ disease. Up to now, curative treatment modalities for the most severe sight-threatening cases have not been developed. Here the authors summarize the treatment protocol of Graves’ orbitopathy and review novel therapeutic options. They review the literature on this topic and present their own clinical experience. The authors point out that anti-CD20 antibody could positively influence the clinical course of Graves’ orbitopathy. Selenium is efficient in mild cases. Further prospective investigations are warranted. Orv. Hetil., 2014, 155(33), 1295–1300.

Exenatide: a novel treatment of Type 2 diabetes

Therapy ◽  
2005 ◽  
Vol 2 (2) ◽  
pp. 207-222 ◽  
Author(s):  
Bo Ahren
Keyword(s):  
Type 2 Diabetes ◽  
Novel Treatment
Sign in / Sign up

Export Citation Format

Share Document